Login or Register for additional
programming information
Program Description
Dr. Flaherty, a national leader in the understanding of signalling pathways and the molecular biology of cancer, discusses how breakthroughs in understanding intracellular pathways will lead to personalized cancer therapy. Agents such as Sorafenib may be among the first substances that will be used in unique combinations to thwart the growth and spread of malignancies. How will these agents be developed, studied and mixed together for the optimum clinical result? How will the intense research needed for this endeavor be funded? How will the future of cancer treatment be altered?
Series
Medical Breakthroughs from Penn Medicine
Guest
Keith Flaherty, MD
Assistant Professor of Medicine
Abramson Cancer Center
Authority on Molecular Genetics of Cancer and extensively published on the concepts of signa...more
Hosted by
Back To Program List